Misuse of pharmaceuticals by regular psychostimulant users is linked to mental health problems
##plugins.themes.bootstrap3.article.main##
Abstract
Introduction. Misuse of pharmaceutical drugs, particularly by young people, is an issue of rising concern. Poly-substance use is common among regular psychostimulant users (RPU), and mental health problems are associated with pharmaceutical misuse, but RPU do not generally acknowledge their use as problematic.
Objective. To examine links between mental health and misuse of non-prescription pharmaceuticals in a group of regular users of illicit psychostimulants.
Method. Face to face structured interviews were conducted in April 2015 with 763 regular users of illicit psychostimulants as part of the Annual Ecstasy and Related Drugs Reporting System study in Australia.
Results. At least half of the RPU in this study reported extra-medical or misuse of pharmaceuticals in the last six months in addition to regular use of illicit psychostimulants. Higher levels of psychological distress were recorded for RPU who also reported recent illicit use of opioids, antidepressants, benzodiazepines, or over-the-counter (OTC) codeine. Recent misuse of benzodiazepines or OTC codeine was associated with self-reported mental health problems and having attended a mental health professional. Those reporting recent misuse of opioids were at increased risk of mental health problems and more likely to record high levels of psychological distress, but less likely to have received prescription medications for their mental health problem.
Discussion and conclusion. Regular users of illicit psychostimulants who also misuse pharmaceuticals are at increased risk of mental health problems, even after accounting for their use of illicit psychostimulants. Screening of this group for mental health problems is recommended.
References
Australian Government. (2012). National Pharmaceutical Drug Misuse Framework for Action (2012-2015). Canberra: Australian Govenrment.
Australian Institute of Health and Welfare. (2017). National Drug Strategy Household Survey 2016: Detailed Findings Drug Statistics. Canberra: Australian Institute of Health and Welfare.
Bachhuber, M. A., Maughan, B. C., Mitra, N., Feingold, J., & Starrels, J. L. (2016). Prescription monitoring programs and emergency department visits involving benzodiazepine misuse: Early evidence from 11 United States metropolitan areas. [Article]. International Journal of Drug Policy, 28, 120-123. doi: 10.1016/j.drugpo.2015.08.005
Connor, J. P., Gullo, M. J., White, A., & Kelly, A. B. (2014). Polysubstance use: diagnostic challenges, patterns of use and health. [Review]. Current Opinion in Psychiatry, 27(4), 269-275. doi: 10.1097/yco.0000000000000069
Darke, S. (1998). Self-report among injecting drug users: A review. Drug & Alcohol Dependence, 51(3), 253-263. doi: 10.1016/s0376-8716(98)00028-3
Dunlop, A. (2011). Harms: How much, how many, how often? Drug and Alcohol Review, 30(3), 332-333. doi: 10.1111/j.1465-3362.2011.00286.x
Hides, L., Lubman, D. I., Devlin, H., Cotton, S., Aitken, C., Gibbie, T., & Hellard, M. (2007). Reliability and Validity of the Kessler 10 and Patient Health Questionnaire among Injecting Drug Users. Australian & New Zealand Journal of Psychiatry, 41(2), 166-168. doi: doi:10.1080/00048670601109949
International Narcotics Control Board. (2016). Availability of Internationally Controlled Drugs: Ensuring adequate access for medical and scientific purposes. New York: United Nations.
Kaye, S., & Darke, S. (2012). The diversion and misuse of pharmaceutical stimulants: what do we know and why should we care? Addiction, 107(3), 467-477. doi: 10.1111/j.1360-0443.2011.03720.x
Kaye, S., Darke, S., & Torok, M. (2014). Diversion and misuse of pharmaceutical stimulants among illicit drug users. Addiction Research & Theory, 22(2), 109-116. doi: 10.3109/16066359.2013.779677
Kelly, B. C., Wells, B. E., Pawson, M., LeClair, A., & Parsons, J. T. (2014). Combinations of prescription drug misuse and illicit drugs among young adults. Addictive Behaviors, 39(5), 941-944. doi: http://dx.doi.org/10.1016/j.addbeh.2013.12.003
Kessler, R., & Mroczek, D. (1994). Final version of our Non-specific Psychological Distress Scale. Ann Arbor (MI): Survey Research Centre of Institute for Social Research, University of Michigan.
Lasopa, S. O., Striley, C. W., & Cottler, L. B. (2015). Diversion of prescription stimulant drugs among 10-18-year-olds. Current Opinion in Psychiatry, 28(4), 292.
Lloyd, B. K., & McElwee, P. R. (2011). Trends over time in characteristics of pharmaceutical drug-related ambulance attendances in Melbourne. Drug and Alcohol Review, 30(3), 271-280. doi: 10.1111/j.1465-3362.2011.00292.x
Lubman, D. I., Allen, N. B., Rogers, N., Cementon, E., & Bonomo, Y. (2007). The impact of co-occurring mood and anxiety disorders among substance-abusing youth. [Article]. Journal of Affective Disorders, 103(1-3), 105-112. doi: 10.1016/j.jad.2007.01.011
Maxwell, J. C. (2011). The prescription drug epidemic in the United States: A perfect storm. Drug and Alcohol Review, 30(3), 264-270. doi: 10.1111/j.1465-3362.2011.00291.x
Medina, K. L., & Shear, P. K. (2007). Anxiety, depression, and behavioral symptoms of executive dysfunction in ecstasy users: Contributions of polydrug use. Drug and Alcohol Dependence, 87(2–3), 303-311. doi: http://dx.doi.org/10.1016/j.drugalcdep.2006.09.003
Nicholas, R., Lee, N., & Roche, A. M. (2011). Pharmaceutical Drug Misuse in Australia: Complex Problems, Balanced Responses. Adelaide: National Centre for Education and Training on Addiction (NCETA).
Nielsen, S., & Bruno, R. (2011). Pharmaceutical drugs: The delicate balance between reducing pain and reducing harm. Drug and Alcohol Review, 30(3), 233-235. doi: 10.1111/j.1465-3362.2011.00326.x
Nielsen, S., & Bruno, R. (2014). Implementing real-time prescription drug monitoring: Are we ready? Drug and Alcohol Review, 33(5), 463-465. doi: 10.1111/dar.12195
Salom, C. L., Betts, K. S., Williams, G. M., Najman, J. M., & Alati, R. (2016). Predictors of comorbid polysubstance use and mental health disorders in young adults—a latent class analysis. Addiction, 111(1), 156-164. doi: 10.1111/add.13058
Sindicich, N., & Burns, L. (2015). Australian trends in ecstasy and related drug markets 2014: Findings from the Ecstasy and Related Drugs Reporting System (EDRS) Australian Drug Trends series. Sydney: National Drug and Alcohol Research Centre, UNSW.
Smith, G. W., Farrell, M., Bunting, B. P., Houston, J. E., & Shevlin, M. (2011). Patterns of polydrug use in Great Britain: Findings from a national household population survey. Drug and Alcohol Dependence, 113(2–3), 222-228. doi: http://dx.doi.org/10.1016/j.drugalcdep.2010.08.010
Wilkins, C., Sweetsur, P., & Griffiths, R. (2011). Recent trends in pharmaceutical drug use among frequent injecting drug users, frequent methamphetamine users and frequent ecstasy users in New Zealand, 2006–2009. Drug and Alcohol Review, 30(3), 255-263. doi: 10.1111/j.1465-3362.2011.00324.x
Worley, J. (2012). Prescription drug monitoring programs, a response to doctor shopping: Purpose, effectiveness, and directions for future research. [Review]. Issues in Mental Health Nursing, 33(5), 319-328. doi: 10.3109/01612840.2011.654046
